DR. ASAD NASIR MD
Prescription History 1346446721
Internal Medicine - Pulmonary Disease in Elmira, NY


Quality Rating: 81.01 out of 100 score

NPI Status: Active since June 22, 2007

Contact Information

600 ROE AVE STE 4A
ELMIRA, NY
ZIP 14905
Phone: (607) 271-3780
Fax: (607) 271-3894

Get Directions

Prescription History for Informed Healthcare Decisions

Explore the verified Medicare Part D prescription history, volume metrics, and calculated drug costs for DR. ASAD NASIR MD, an active Pulmonary Disease specialist practicing in Elmira, NY. Our medical registry currently tracks 30 unique pharmaceutical formulations prescribed by this provider, representing an estimated volume of 1,702 documented patient claims. Among these therapy options, the most frequently utilized medication is Albuterol Sulfate Hfa, which accounts for 436 claims alone.


Advair Diskus

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 41
30-Day Fills 53.0
Days Supply 1,590
NY State Average Benchmarks
Peer Average Claims26.0
Peer Average 30-Day Fills36.8
Peer Average Days Supply1,100
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 57.7% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $24,276.74 across this reporting matrix range.

Provider Avg Cost Per Claim

$592.12

State Avg Cost Per Claim

$588.17

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Advair Hfa

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 25
30-Day Fills 31.0
Days Supply 930
NY State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills27.8
Peer Average Days Supply834
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $14,943.15 across this reporting matrix range.

Provider Avg Cost Per Claim

$597.73

State Avg Cost Per Claim

$616.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Albuterol Sulfate Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 436
30-Day Fills 536.5
Days Supply 12,743
NY State Average Benchmarks
Peer Average Claims66.0
Peer Average 30-Day Fills79.4
Peer Average Days Supply2,056
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 560.6% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $18,400.54 across this reporting matrix range.

Provider Avg Cost Per Claim

$42.20

State Avg Cost Per Claim

$47.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Amoxicillin-Clavulanate Potass

Generic Formulation: Amoxicillin/Potassium ClavSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 165
NY State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills25.2
Peer Average Days Supply225
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $161.44 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.07

State Avg Cost Per Claim

$12.45

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A fixed-ratio combination of amoxicillin trihydrate and potassium clavulanate.

Therapeutic Applications

Amoxicillin/clavulanic acid is a combination penicillin-type antibiotic used to treat a wide variety of bacterial infections. It works by stopping the growth of bacteria. This antibiotic treats only bacterial infections. It will not work for viral infections (such as common cold, flu). Using any antibiotic when it is not needed can cause it to not work for future infections.

Anoro Ellipta

Generic Formulation: Umeclidinium Brm/Vilanterol TrSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 54
30-Day Fills 88.0
Days Supply 2,640
NY State Average Benchmarks
Peer Average Claims35.0
Peer Average 30-Day Fills46.1
Peer Average Days Supply1,372
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 54.3% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $42,802.91 across this reporting matrix range.

Provider Avg Cost Per Claim

$792.65

State Avg Cost Per Claim

$600.87

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: umeclidinium and vilanterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Vilanterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Umeclidinium/vilanterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as vilanterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Arnuity Ellipta

Generic Formulation: Fluticasone FuroateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 27.0
Days Supply 810
NY State Average Benchmarks
Peer Average Claims27.0
Peer Average 30-Day Fills35.9
Peer Average Days Supply1,073
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $5,962.73 across this reporting matrix range.

Provider Avg Cost Per Claim

$259.25

State Avg Cost Per Claim

$300.92

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Azithromycin

Generic Formulation: AzithromycinSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 84
30-Day Fills 158.8
Days Supply 4,313
NY State Average Benchmarks
Peer Average Claims38.0
Peer Average 30-Day Fills39.4
Peer Average Days Supply295
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 121.1% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,759.12 across this reporting matrix range.

Provider Avg Cost Per Claim

$20.94

State Avg Cost Per Claim

$8.47

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A semi-synthetic macrolide antibiotic structurally related to ERYTHROMYCIN. It has been used in the treatment of Mycobacterium avium intracellulare infections, toxoplasmosis, and cryptosporidiosis.

Therapeutic Applications

This medication is used to treat certain eye infections. It is a macrolide antibiotic that works by stopping the growth of bacteria. This medication treats only bacterial eye infections. It will not work for other types of eye infections. Unnecessary use or misuse of any antibiotic can lead to its decreased effectiveness.

Breo Ellipta

Generic Formulation: Fluticasone/VilanterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 134
30-Day Fills 178.0
Days Supply 5,340
NY State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills50.0
Peer Average Days Supply1,491
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 262.2% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $73,503.05 across this reporting matrix range.

Provider Avg Cost Per Claim

$548.53

State Avg Cost Per Claim

$531.93

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to prevent and decrease symptoms (wheezing and trouble breathing) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, including chronic bronchitis and emphysema). This inhaler contains 2 medications: fluticasone and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the swelling of the airways in the lungs to make breathing easier. Vilanterol belongs to a class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. When used alone, long-acting beta agonists (like vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Breztri Aerosphere

Generic Formulation: Budesonide/Glycopyr/FormoterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 23
30-Day Fills 23.0
Days Supply 690
NY State Average Benchmarks
Peer Average Claims41.0
Peer Average 30-Day Fills52.7
Peer Average Days Supply1,578
Conservative Utilization

This provider writes prescriptions for this formulation 43.9% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $15,575.37 across this reporting matrix range.

Provider Avg Cost Per Claim

$677.19

State Avg Cost Per Claim

$799.94

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you maintain your normal activities and decreases time lost from work or school. This inhaler contains 3 medications: budesonide, glycopyrrolate, and formoterol. Budesonide works by reducing the irritation and swelling of the airways. Budesonide belongs to a class of drugs known as corticosteroids. Glycopyrrolate and formoterol work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Glycopyrrolate belongs to a class of drugs known as anticholinergics. Formoterol belongs to the class of drugs known as long-acting beta agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This medication is not approved to treat asthma.

Budesonide-Formoterol Fumarate

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NY State Average Benchmarks
Peer Average Claims18.0
Peer Average 30-Day Fills22.5
Peer Average Days Supply672
Conservative Utilization

This provider writes prescriptions for this formulation 33.3% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,873.38 across this reporting matrix range.

Provider Avg Cost Per Claim

$239.45

State Avg Cost Per Claim

$361.98

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Combivent Respimat

Generic Formulation: Ipratropium/Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 30
30-Day Fills 38.0
Days Supply 1,130
NY State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills28.3
Peer Average Days Supply835
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 30.4% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $19,341.51 across this reporting matrix range.

Provider Avg Cost Per Claim

$644.72

State Avg Cost Per Claim

$591.76

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to treat and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). This product contains 2 medications: ipratropium and albuterol (also known as salbutamol). Both drugs work by relaxing the muscles around the airways so that the airways open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Eliquis

Generic Formulation: ApixabanSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 11
30-Day Fills 11.0
Days Supply 330
NY State Average Benchmarks
Peer Average Claims78.0
Peer Average 30-Day Fills127.9
Peer Average Days Supply3,554
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 85.9% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $6,004.79 across this reporting matrix range.

Provider Avg Cost Per Claim

$545.89

State Avg Cost Per Claim

$816.86

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Apixaban is used to prevent serious blood clots from forming due to a certain irregular heartbeat (atrial fibrillation) or after hip/knee replacement surgery. With atrial fibrillation, part of the heart does not beat the way it should. This can lead to blood clots forming, which can travel to other parts of your body (such as the lungs or legs) or increase your risk for stroke. In the United States, apixaban is also approved to treat certain types of blood clots (deep vein thrombosis-DVT, pulmonary embolus-PE) and to prevent them from forming again. Apixaban is an anticoagulant that works by blocking certain clotting proteins in your blood.

Fasenra Pen

Generic Formulation: BenralizumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 22.4
Days Supply 672
NY State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills28.5
Peer Average Days Supply848
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $77,685.42 across this reporting matrix range.

Provider Avg Cost Per Claim

$6,473.79

State Avg Cost Per Claim

$5,694.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Benralizumab is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Flovent Hfa

Generic Formulation: Fluticasone PropionateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 18
30-Day Fills 27.3
Days Supply 820
NY State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills34.1
Peer Average Days Supply1,020
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $9,086.94 across this reporting matrix range.

Provider Avg Cost Per Claim

$504.83

State Avg Cost Per Claim

$405.04

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A STEROID with GLUCOCORTICOID RECEPTOR activity that is used to manage the symptoms of ASTHMA; ALLERGIC RHINITIS, and ATOPIC DERMATITIS.

Therapeutic Applications

Fluticasone is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you maintain your normal activities and decreases time lost from work or school. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling (inflammation) of the airways in the lungs to make breathing easier. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Fluticasone-Salmeterol

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 52
30-Day Fills 66.0
Days Supply 1,980
NY State Average Benchmarks
Peer Average Claims23.0
Peer Average 30-Day Fills31.5
Peer Average Days Supply944
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 126.1% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $10,766.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$207.05

State Avg Cost Per Claim

$245.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Furosemide

Generic Formulation: FurosemideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 25.4
Days Supply 762
NY State Average Benchmarks
Peer Average Claims72.0
Peer Average 30-Day Fills131.7
Peer Average Days Supply3,744
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 83.3% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $43.86 across this reporting matrix range.

Provider Avg Cost Per Claim

$3.66

State Avg Cost Per Claim

$6.06

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A benzoic-sulfonamide-furan. It is a diuretic with fast onset and short duration that is used for EDEMA and chronic RENAL INSUFFICIENCY.

Therapeutic Applications

Furosemide is used to reduce extra fluid in the body (edema) caused by conditions such as heart failure, liver disease, and kidney disease. This can lessen symptoms such as shortness of breath and swelling in your arms, legs, and abdomen. This drug is also used to treat high blood pressure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. Furosemide is a water pill (diuretic) that causes you to make more urine. This helps your body get rid of extra water and salt.

Incruse Ellipta

Generic Formulation: Umeclidinium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 71
30-Day Fills 79.0
Days Supply 2,370
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills39.9
Peer Average Days Supply1,175
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 129.0% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $29,123.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$410.18

State Avg Cost Per Claim

$468.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Umeclidinium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Umeclidinium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Montelukast Sodium

Generic Formulation: Montelukast SodiumSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 47
30-Day Fills 101.0
Days Supply 3,017
NY State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills108.8
Peer Average Days Supply3,230
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $606.63 across this reporting matrix range.

Provider Avg Cost Per Claim

$12.91

State Avg Cost Per Claim

$15.11

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Montelukast is used to control and prevent symptoms caused by asthma (such as wheezing and shortness of breath). It is also used before exercise to prevent breathing problems during exercise (bronchospasm). This medication can help decrease the number of times you need to use your quick relief inhaler. Montelukast is also used to relieve symptoms of hay fever and allergic rhinitis (such as sneezing, stuffy/runny/itchy nose). Since there are other allergy medications that may be safer (see also Warning section), this medication should be used for this condition only when you cannot take other allergy medications or they do not work well. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack or sudden shortness of breath occurs, use your quick-relief inhaler as prescribed. This drug works by blocking certain natural substances (leukotrienes) that may cause or worsen asthma and allergies. It helps make breathing easier by reducing swelling (inflammation) in the airways.

Nucala

Generic Formulation: MepolizumabSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 19
30-Day Fills 19.0
Days Supply 532
NY State Average Benchmarks
Peer Average Claims24.0
Peer Average 30-Day Fills25.9
Peer Average Days Supply733
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $74,961.53 across this reporting matrix range.

Provider Avg Cost Per Claim

$3,945.34

State Avg Cost Per Claim

$4,259.69

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used along with other medications to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma. Controlling symptoms of asthma helps you do your normal activities and decreases time lost from work or school. Mepolizumab is also used to treat certain other immune system disorders (chronic rhinosinusitis with nasal polyps, eosinophilic granulomatosis with polyangiitis, hypereosinophilic syndrome). This medication works by decreasing a certain type of white blood cell (eosinophils). This effect helps reduce swelling (inflammation) of the airways to make breathing easier. It may also help reduce the size of nasal polyps, and lessen symptoms such as runny/stuffy nose, mucus in the throat, loss of smell, facial pain, and tiredness. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks or breathing problems. If an asthma attack occurs, use your quick-relief inhaler as prescribed.

Ofev

Generic Formulation: Nintedanib EsylateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 20
30-Day Fills 20.0
Days Supply 600
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills32.2
Peer Average Days Supply961
Conservative Utilization

This provider writes prescriptions for this formulation 35.5% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $288,918.65 across this reporting matrix range.

Provider Avg Cost Per Claim

$14,445.93

State Avg Cost Per Claim

$12,552.66

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This medication is used to treat certain types of lung disease (idiopathic pulmonary fibrosis- IPF, interstitial lung disease). Both types of lung disease scar and stiffen your lungs, making it hard to breathe. Nintedanib may help slow down the worsening of your lung disease.

Prednisone

Generic Formulation: PrednisoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 66
30-Day Fills 82.0
Days Supply 1,581
NY State Average Benchmarks
Peer Average Claims44.0
Peer Average 30-Day Fills53.3
Peer Average Days Supply1,023
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 50.0% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $566.82 across this reporting matrix range.

Provider Avg Cost Per Claim

$8.59

State Avg Cost Per Claim

$6.20

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A synthetic anti-inflammatory glucocorticoid derived from CORTISONE. It is biologically inert and converted to PREDNISOLONE in the liver.

Therapeutic Applications

Prednisone is used to treat conditions such as arthritis, blood disorders, breathing problems, severe allergies, skin diseases, cancer, eye problems, and immune system disorders. Prednisone belongs to a class of drugs known as corticosteroids. It decreases your immune system's response to various diseases to reduce symptoms such as swelling and allergic-type reactions.

Roflumilast

Generic Formulation: RoflumilastSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 22.0
Days Supply 660
NY State Average Benchmarks
Peer Average Claims17.0
Peer Average 30-Day Fills28.1
Peer Average Days Supply827
Conservative Utilization

This provider writes prescriptions for this formulation 29.4% less frequently than the standard regional baseline metric for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $1,646.30 across this reporting matrix range.

Provider Avg Cost Per Claim

$137.19

State Avg Cost Per Claim

$364.54

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

Roflumilast is used to control and prevent symptoms (wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis). It should be used along with other medications (bronchodilators such as salmeterol, ipratropium) to treat COPD. It works by reducing the irritation and swelling of the airways. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath or wheezing. If sudden breathing problems occur, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spiriva Respimat

Generic Formulation: Tiotropium BromideSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 108
30-Day Fills 136.0
Days Supply 4,080
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills44.4
Peer Average Days Supply1,331
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 248.4% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $71,391.17 across this reporting matrix range.

Provider Avg Cost Per Claim

$661.03

State Avg Cost Per Claim

$695.14

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A scopolamine derivative and CHOLINERGIC ANTAGONIST that functions as a BRONCHODILATOR AGENT. It is used in the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

Tiotropium is used to control and prevent symptoms (such as wheezing, shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD which includes bronchitis and emphysema). It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If wheezing or sudden shortness of breath occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Spironolactone

Generic Formulation: SpironolactoneSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 12.0
Days Supply 360
NY State Average Benchmarks
Peer Average Claims37.0
Peer Average 30-Day Fills78.8
Peer Average Days Supply2,328
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 67.6% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $175.80 across this reporting matrix range.

Provider Avg Cost Per Claim

$14.65

State Avg Cost Per Claim

$12.16

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A potassium sparing diuretic that acts by antagonism of aldosterone in the distal renal tubules. It is used mainly in the treatment of refractory edema in patients with congestive heart failure, nephrotic syndrome, or hepatic cirrhosis. Its effects on the endocrine system are utilized in the treatments of hirsutism and acne but they can lead to adverse effects. (From Martindale, The Extra Pharmacopoeia, 30th ed, p827)

Therapeutic Applications

Spironolactone is used to treat high blood pressure and heart failure. Lowering high blood pressure helps prevent strokes, heart attacks, and kidney problems. It is also used to treat swelling (edema) caused by certain conditions (such as heart failure, liver disease) by removing excess fluid and improving symptoms such as breathing problems. This medication is also used to treat conditions in which the body is making too much of a natural substance (aldosterone). Spironolactone is known as a water pill (potassium-sparing diuretic).

Stiolto Respimat

Generic Formulation: Tiotropium Br/Olodaterol HclSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 49
30-Day Fills 59.0
Days Supply 1,770
NY State Average Benchmarks
Peer Average Claims31.0
Peer Average 30-Day Fills42.9
Peer Average Days Supply1,286
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 58.1% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $28,523.08 across this reporting matrix range.

Provider Avg Cost Per Claim

$582.10

State Avg Cost Per Claim

$633.88

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 2 medications: tiotropium and olodaterol. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Tiotropium belongs to a class of drugs known as anticholinergics. Olodaterol belongs to the class of drugs known as long-acting inhaled beta-agonists (LABAs). Both drugs are also known as bronchodilators. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed. Tiotropium/olodaterol is not approved to treat asthma. People with asthma using long-acting inhaled beta agonists (such as olodaterol) without also using an inhaled corticosteroid may have an increased risk of serious (sometimes fatal) breathing problems.

Symbicort

Generic Formulation: Budesonide/Formoterol FumarateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 120
30-Day Fills 160.0
Days Supply 4,799
NY State Average Benchmarks
Peer Average Claims36.0
Peer Average 30-Day Fills49.7
Peer Average Days Supply1,490
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 233.3% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $59,710.52 across this reporting matrix range.

Provider Avg Cost Per Claim

$497.59

State Avg Cost Per Claim

$516.71

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A pharmaceutical preparation of budesonide and formoterol fumarate that is used as an ANTI-ASTHMATIC AGENT and for the treatment of CHRONIC OBSTRUCTIVE PULMONARY DISEASE.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: budesonide and formoterol. Budesonide belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Formoterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as formoterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. Before using this medication, it is important to learn how to use it properly. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed. See also How to Use section.

Theophylline Er

Generic Formulation: Theophylline AnhydrousSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 12
30-Day Fills 30.0
Days Supply 900
NY State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills36.9
Peer Average Days Supply1,090
Highly Conservative Utilization

This provider demonstrates a highly selective approach to this formula, recording 52.0% less volume than the regional standard for practitioners inside NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $2,994.71 across this reporting matrix range.

Provider Avg Cost Per Claim

$249.56

State Avg Cost Per Claim

$158.40

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A drug combination that contains THEOPHYLLINE and ethylenediamine. It is more soluble in water than theophylline but has similar pharmacologic actions. It's most common use is in bronchial asthma, but it has been investigated for several other applications.

Therapeutic Applications

Theophylline is used to treat lung diseases such as asthma and COPD (bronchitis, emphysema). It must be used regularly to prevent wheezing and shortness of breath. This medication belongs to a class of drugs known as xanthines. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. It also decreases the lungs' response to irritants. Controlling symptoms of breathing problems can decrease time lost from work or school. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden breathing problems. If sudden shortness of breath occurs, use your quick-relief inhaler as prescribed.

Trelegy Ellipta

Generic Formulation: Fluticasone/Umeclidin/VilanterSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 121
30-Day Fills 171.0
Days Supply 5,130
NY State Average Benchmarks
Peer Average Claims55.0
Peer Average 30-Day Fills73.7
Peer Average Days Supply2,206
Highly Elevated Utilization

This provider exhibits a high preference for this treatment path, registering a volume 120.0% higher than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $109,728.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$906.85

State Avg Cost Per Claim

$849.96

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (such as wheezing and shortness of breath) caused by asthma and ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). Controlling symptoms of breathing problems helps you stay active. This inhaler contains 3 medications: fluticasone, umeclidinium, and vilanterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing swelling of the airways in the lungs to make breathing easier. Umeclidinium belongs to a class of drugs known as anticholinergics and vilanterol is a LABA medication. Both drugs work by relaxing the muscles around the airways so that they open up and you can breathe more easily. Both drugs are also known as bronchodilators. When used alone, long-acting beta agonists (such as vilanterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination products containing both an inhaled corticosteroid and long-acting beta agonist, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with two asthma-control medications (such as inhaled corticosteroid and long-acting beta agonist) or if your symptoms need combination treatment. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden shortness of breath. If sudden breathing problems occur, use your quick-relief inhaler as prescribed.

Ventolin Hfa

Generic Formulation: Albuterol SulfateSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 37
30-Day Fills 41.2
Days Supply 1,020
NY State Average Benchmarks
Peer Average Claims25.0
Peer Average 30-Day Fills29.8
Peer Average Days Supply769
Elevated Utilization

This provider maintains an active emphasis on this therapeutic option, recording 48.0% more claims than the standard regional baseline profile for NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $3,040.83 across this reporting matrix range.

Provider Avg Cost Per Claim

$82.18

State Avg Cost Per Claim

$75.39

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Clinical Summary

A short-acting beta-2 adrenergic agonist that is primarily used as a bronchodilator agent to treat ASTHMA. Albuterol is prepared as a racemic mixture of R(-) and S(+) stereoisomers. The stereospecific preparation of R(-) isomer of albuterol is referred to as levalbuterol.

Therapeutic Applications

Albuterol (also known as salbutamol) is used to treat wheezing and shortness of breath caused by breathing problems such as asthma. It is a quick-relief medication. Albuterol belongs to a class of drugs known as bronchodilators. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school.

Wixela Inhub

Generic Formulation: Fluticasone Propion/SalmeterolSpecialty: Pulmonary Disease
Provider Metrics Summary
Total Claims 21
30-Day Fills 21.0
Days Supply 630
NY State Average Benchmarks
Peer Average Claims21.0
Peer Average 30-Day Fills31.8
Peer Average Days Supply953
Standard Average Utilization

This provider's prescribing patterns for this therapeutic formulation sit directly in line with standard baseline averages across NY. Gross expenditures recorded under Medicare program tracking definitions for this provider calculate to an estimated aggregate of $4,247.64 across this reporting matrix range.

Provider Avg Cost Per Claim

$202.27

State Avg Cost Per Claim

$285.27

Note on Expenses: These indicators represent gross infrastructure resource tracking paid directly to supply pharmacy networks by Medicare Part D configurations. These calculations do not track individual patient insurance tier copays or out-of-pocket shelf prices at retail checkout lanes.

Therapeutic Applications

This product is used to control and prevent symptoms (wheezing and shortness of breath) caused by asthma or ongoing lung disease (chronic obstructive pulmonary disease-COPD, which includes chronic bronchitis and emphysema). It contains 2 medications: fluticasone and salmeterol. Fluticasone belongs to a class of drugs known as corticosteroids. It works by reducing the irritation and swelling of the airways. Salmeterol belongs to the class of drugs known as long-acting beta agonists. It works by relaxing the muscles around the airways so that they open up and you can breathe more easily. Controlling symptoms of breathing problems can decrease time lost from work or school. When used alone, long-acting beta agonists (such as salmeterol) may rarely increase the risk of serious (sometimes fatal) asthma-related breathing problems. However, combination inhaled corticosteroid and long-acting beta agonists, such as this product, do not increase the risk of serious asthma-related breathing problems. For asthma treatment, this product should be used when breathing problems are not well controlled with one asthma-control medication (such as inhaled corticosteroid) or if your symptoms need combination treatment. Before using this medication, it is important to learn how to use it properly. This medication must be used regularly to be effective. It does not work right away and should not be used to relieve sudden asthma attacks. If an asthma attack occurs, use your quick-relief inhaler (such as albuterol, also called salbutamol in some countries) as prescribed.

Dataset Methodology & CMS Source Information

This analytical profile maps public infrastructure records sourced directly from official **Centers for Medicare & Medicaid Services (CMS)** public data releases. The statistics above track documented pharmaceutical treatment trends assigned to beneficiaries specifically under federal public programs. Evaluating the prescriptive footprints of clinical practitioners like DR. ASAD NASIR MD provides transparency into local medical care patterns within Elmira, NY.

Key Learning Objectives for this Profile:

  • Prescribing Frequencies: Track and evaluate the volume metrics of specific brand-name and generic medical formulas chosen by this provider over time.
  • Clinical Focus Areas: Identify how the provider distributes therapeutic selections across medical care options to gain insight into their true day-to-day **Pulmonary Disease** practice concentrations.
  • Program Cost Awareness: Review the calculated total systemic drug costs and raw transactional volumes linked to these orders to better anticipate network insurance coverage structures.
  • Patient-Centered Evaluation: Cross-reference localized regional care comparisons to align practitioner habits directly with your proactive health maintenance goals.

Data Scope Exclusion & Limitations: The data elements presented above explicitly reflect prescription orders processed for Medicare beneficiaries during the year 2023. This informational profile does not aggregate prescription data for individuals utilizing private commercial health plans, state Medicaid coverage, or self-pay options. However, because medical decision-making remains highly consistent across clinical settings, this public registry provides a reliable proxy for understanding the general prescribing preferences and pharmaceutical care approach used by this provider.